Clinical Trial Update: Envarsus XL Immunosuppression Following Liver Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Envarsus XL for immunosuppression after liver transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplant Recipients

Drugs mentioned

• Envarsus XL (tacrolimus extended-release formulation)

Snippet

Sponsor: Methodist Healthcare | Conditions: Recipients of Liver Transplant | Phase 2 | Status: COMPLETED